Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense

Exclusion Criteria

• •1. Stable and continued use of medication for allergic pathology during 2 weeks prior to inclusion.
• •2. Patients sensitised to other overlapping seasonal allergens and with specific IgE levels greater or equal to class 2 CAP/PHADIA.
• •3. Patients who received immunotherapy in the previous 5 years for Phleum pratense or for any allergen with cross reactivity or patients that are currently receiving immunotherapy for any allergen.
• •4. Patients with severe asthma or FEV1 lower than 60% or asthma requiring inhaled or systemic corticoid treatment at the time of study entry or within 8 weeks prior to treatment commencement.
• •5. Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study.
• •6. Patients with a previous history of anaphylaxis
• •7. Patients with unstable angina
• •8. Patients with uncontrolled hypertension
• •9. Patients with clinically significant arrythmias
• •10. Patients with neoplasia
• •11. Patients with clinically relevant malformations of the upper respiratory tract.
• •12. Other chronic or immunological disease that could interfere with the assessment of the investigation product or that could generate any additional risk for the patient
• •13. Patients who have participated in another clinical trial within 3 month prior to enrolment.
• •14. Patients under treatment with tricyclic antidepressives, psychotropics or beta-blockers
• •15. Female patients who are pregnant or breast-feeding or women of childbearing potential that do not agree to use an appropriate contraception method during the study if they are sexually active, if they have not been surgical sterilised or present any other incapacity to bear
• •16. Patient who does not attend the visits
• •17. Patient's lack of collaboration or refusal to participate.